Advances in CAR T-Cell Therapy for Leukemia, Lymphoma, and Myeloma: Where We Are and Where We Are Going

In this online program, experts discuss best practices and emerging strategies in CAR T-cell therapy for patients with leukemia, lymphoma, and myeloma. Watch the on-demand Webcast, download the slides from a dynamic CCO symposium in Orlando, and read expert commentaries to learn more about how to integrate CAR T-cells into your clinical practice.
Matthew J. Frigault, MD
Jae H. Park, MD
person default
Stephen J. Schuster, MD


Review my approach to CAR T-cell therapy—including considerations for patient candidacy and managing toxicities—illustrated with a patient case from my practice.

person default Stephen J. Schuster, MD Released: October 17, 2019

In this commentary, Matthew J. Frigault, MD, highlights key studies of CAR T-cell therapy that will be presented at the upcoming 2019 ASH annual meeting in Orlando.

Matthew J. Frigault, MD Released: December 4, 2019

Read expert answers to audience questions from a recent symposium on current best practices and emerging directions in CAR T-cell therapy.

Jae H. Park, MD Released: March 24, 2020
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by an educational grant from
Celgene Corporation
Kite, A Gilead Company

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.